GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. This advancement is supported by positive results from a phase II ...

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid ...

GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.  | GSK is ...

Sept 1 (Reuters) - GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate to a late-stage trial after mid-stage data showed it generated stronger immune responses than ...

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at ...

With respiratory virus season approaching, GSK is preparing to begin a Phase 3 clinical trial evaluating its experimental messenger RNA vaccine for seasonal influenza. The vaccine maker revealed the ...

GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data · Results showed higher immune responses ver ...

GSK’s mRNA flu vaccine enters Phase III after positive results, putting the drugmaker closer to competing with Moderna in the evolving flu vaccine market.

GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, emboldening the company to start a pivotal study this month. The limited, ...

MRNA climbed 6% as traders read GSK's Phase III mRNA flu commitment as platform validation rather than a competitive threat to mFlusvia. Moderna's Phase III melanoma win with MRK as co-developer ...